Abbott
This article was originally published in The Gray Sheet
Executive Summary
FDA inspection of Murex' SUDS rapid HIV-1 test manufacturing was not related to the October closure of the Abbott subsidiary's Norcross, Georgia plant, the firm states. Although the firm planned to resume production in November (1"The Gray Sheet" Oct. 23, 2000, p. 24), it has not yet completed an investigation initiated after the test failed to meet internal specifications. An FDA inspection in August revealed QSR violations, including failure to submit information regarding tests affected by high background/false positive problems and failure to clarify steps that will be taken to investigate negative control and leaking bottle problems, according to a Dec. 15 FDA warning letter
You may also be interested in...
Abbott HIV P24 Antigen Test Recall Limited To About 350 Kits
A firm-initiated recall of Abbott's HIVAG-1 monoclonal HIV p24 antigen test kits initiated Feb. 13 stems from underfilled antibody vials and is limited to a single lot of about 350 test kits.
Abbott HIV P24 Antigen Test Recall Limited To About 350 Kits
A firm-initiated recall of Abbott's HIVAG-1 monoclonal HIV p24 antigen test kits initiated Feb. 13 stems from underfilled antibody vials and is limited to a single lot of about 350 test kits.
Abbott Investigating SUDS HIV-1 Test Production Problems, Exhausts Supply
Production of Abbott Laboratories' single-use diagnostic system (SUDS) HIV-1 rapid test could resume within the next 30 days, the firm says following a halt in production due to a failure to meet certain panel and negative control specifications.